Palvella Therapeutics Inc (PVLA)

$25.39 -0.08 (-0.31%)
Market Cap 280.65M
Revenue (ttm) 0.00
Net Income (ttm) -17.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 65,900
Avg Vol 81,910
Day's Range N/A - N/A
Shares Out 11.02M
Stochastic %K 58%
Beta 0.10
Analysts Strong Sell
Price Target $49.38

Latest News on PVLA

Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology

Apr 23, 2025, 4:15 PM EDT - 2 days ago

Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology

Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Apr 22, 2025, 7:30 AM EDT - 3 days ago

Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University's Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology

Apr 11, 2025, 7:30 AM EDT - 14 days ago

Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University's Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology

Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology

Apr 2, 2025, 8:00 AM EDT - 23 days ago

Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology

Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 31, 2025, 7:30 AM EDT - 25 days ago

Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025

Mar 18, 2025, 8:30 AM EDT - 5 weeks ago

Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025

Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference

Feb 25, 2025, 8:00 AM EST - 2 months ago

Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old

Feb 10, 2025, 8:00 AM EST - 2 months ago

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old

Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million

Dec 13, 2024, 2:55 PM EST - 4 months ago

Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million